Cargando…
Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
BACKGROUND & OBJECTIVES: An association between over-expression of proto-oncogene Her-2/neu and resistance to tamoxifen in estrogen receptor (ER) positive, primary and metastatic breast cancer has been suggested. HR+/Her-2/neu+ patients have a poor response to endocrine therapy, making this grou...
Autores principales: | James, Rani, Thriveni, K., Krishnamoorthy, Lakshmi, Deshmane, Vijayalaxmi, Bapsy, P.P., Ramaswamy, Girija |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100149/ https://www.ncbi.nlm.nih.gov/pubmed/21321422 |
Ejemplares similares
-
Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012) -
Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009) -
HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007) -
Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status
por: Tsakountakis, Nikos, et al.
Publicado: (2005) -
Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)